LoDoCo2 Trial: low-dose colchicine reduced the risk of major cardiovascular events in patients with CAD ATPCI: Trimetazidine in Angina Patients With Recent Successful Percutaneous Coronary Intervention RAPID CTCA :Early Coronary CT Angiography in Patients With Suspected or Provisionally Diagnosed Acute Coronary Syndrome OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

1. Latest Trials on CAD from
2020 ESC Congress
2020, Nov
Dr Han Naung Tun, MBBS, MD
Cardiovascular Physician-scientist
ESC Clinical and Research Working Group

2. • LoDoCo2 Trial: low-dose colchicine reduced the risk of major
cardiovascular events in patients with CAD
• ATPCI: Trimetazidine in Angina Patients With Recent Successful
Percutaneous Coronary Intervention
• RAPID CTCA :Early Coronary CT Angiography in Patients With Suspected or
Provisionally Diagnosed Acute Coronary Syndrome
• OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

3. LoDoCo2 Trial: low-dose colchicine
reduced the risk of major cardiovascular
events in patients with CAD
Stefan M. Nidorf et al , NEJM , 2020
ATPCI: Trimetazidine in Angina
Patients With Recent Successful
Percutaneous Coronary Intervention
ATPCI trial
Trimetazidine in
patients with
angina after
successful PCI
shows no
benefit
Roberto Ferrari et al, ATPCI Trial, Lancet 2020

4. Early Coronary CT Angiography in Patients With
Suspected or Provisionally Diagnosed Acute
Coronary Syndrome - RAPID CTCA
RAPID CTCA Trial investigators
OCT and MRI Find an MI Cause in
85% of Women With MINOCA:
HARP
RAPID-CTCA: Early CTCA
in intermediate/high-
risk pts with suspected
ACS at ED
-No difference in all-
cause
death/subsequent MI
-No effect on the
overall Rx & prevention
of ACS or one-year
outcomes
~50% non-obstructive
CAD
The findings support a role for OCT on top of
CMR, already urged by guidelines. How
outcomes might change remains unclear
Reynolds HR at al, MINOCA HARP, Circulation 2020

6. Thank You